Scienture (SCNX) 10-Q 4 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 01, 2020
Document And Entity Information
Entity Registrant Name	TRXADE GROUP, INC.
Entity Central Index Key	0001382574
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		7,702,335
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current Assets
Cash	$ 7,701,305	$ 2,871,694
Accounts Receivable, net	877,097	792,050
Inventory	368,401	56,761
Prepaid Assets	267,375	82,452
Deposits for Inventory purchases	580,800
Total Current Assets	9,794,978	3,802,957
Property Plant and Equipment, Net	197,242	174,987
Other Assets
Deposits	21,636	21,636
Deferred Offering Costs		88,231
Right of use leased assets	734,075	757,710
Goodwill	725,973	725,973
Total Assets	11,473,904	5,571,494
Current Liabilities
Accounts Payable	320,238	334,614
Accrued Liabilities	233,560	98,852
Current Portion Lease Liabilities	90,759	87,350
Customer Deposits	305,972
Total Current Liabilities	950,529	520,816
Long Term Liabilities
Notes Payable - Related Parties	225,000	225,000
Other Long-term Liabilities - Leases	661,078	685,461
Total Liabilities	1,836,607	1,431,277
Shareholders' Equity
Series A Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; none issued and outstanding as of March 31, 2020 and December 31, 2019, respectfully
Common Stock, $0.00001 par value; 100,000,000 shares authorized; 7,484,370 and 6,539,415 shares issued and outstanding, as of March 31, 2020 and December 31, 2019, respectively	75	65
Additional Paid-in Capital	17,852,422	12,535,655
Retained Deficit	(8,215,200)	(8,395,503)
Total Shareholders' Equity	9,637,297	4,140,217
Total Liabilities and Shareholders' Equity	$ 11,473,904	$ 5,571,494

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Series A Preferred stock, par value	$ 0.00001	$ 0.00001
Series A Preferred stock, shares authorized	10,000,000	10,000,000
Series A Preferred stock, shares issued
Series A Preferred stock, shares outstanding
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	7,484,370	6,539,415
Common stock, shares outstanding	7,484,370	6,539,415

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenues	$ 2,203,320	$ 1,512,521
Cost of Sales	563,184	365,839
Gross Profit	1,640,136	1,146,682
Operating Expenses
General and Administrative	1,451,909	974,923
Operating Income	188,227	171,759
Share in Equity Loss Investment		(28,972)
Interest Expense, net	(7,924)	(17,558)
Net Income	$ 180,303	$ 125,229
Net Income per Common Share - Basic:	$ 0.03	$ 0.02
Net Income per Common Share - Diluted:	$ 0.02	$ 0.02
Weighted average Common Shares Outstanding Basic	6,971,427	5,560,695
Weighted average Common Shares Outstanding Diluted	7,423,669	5,998,056

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018		$ 55	$ 8,955,688	$ (8,111,075)	$ 844,668
Balance, shares at Dec. 31, 2018		5,547,638
Common Stock issued for convertible debt and accrued interest		$ 1	211,982		211,983
Common Stock issued for convertible debt and accrued interest, shares		70,666
Warrants Exercised for Cash			166		166
Warrants Exercised for Cash, shares		2,778
Warrant Expense
Options Expense			35,979		35,979
Net Income/Loss				125,229	125,229
Balance at Mar. 31, 2019		$ 56	9,203,815	(7,985,846)	1,218,025
Balance, shares at Mar. 31, 2019		5,621,082
Balance at Dec. 31, 2019		$ 65	12,535,655	(8,395,503)	4,140,217
Balance, shares at Dec. 31, 2019		6,539,415
Warrants Exercised for Cash			1,352		1,352
Warrants Exercised for Cash, shares		22,529
Common Stock issued from offering		$ 10	5,994,414		5,994,424
Common Stock issued from offering, shares		922,219
Fractional shares issued due to reverse split
Fractional shares issued due to reverse split, shares		40
Stock Issuance Costs			(820,586)		(820,586)
Options Exercised for Cash			501		$ 501
Options Exercised for Cash, shares		167			167
Warrant Expense			79,089		$ 79,089
Options Expense			61,997		61,997
Net Income/Loss				180,303	180,303
Balance at Mar. 31, 2020		$ 75	$ 17,852,422	$ (8,215,200)	$ 9,637,297
Balance, shares at Mar. 31, 2020		7,484,370

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Operating Activities:
Net Income	$ 180,303	$ 125,229
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation Expense	1,250	1,250
Options expense	61,997	35,979
Warrant Expense	79,089
Bad Debt Expense	9,000
Share in Equity Losses in Investment		28,972
Amortization of right to use asset	23,635	21,744
Changes in operating assets and liabilities:
Accounts Receivable	(94,047)	(295,169)
Prepaid Assets and other Current Assets	(184,923)	(84,621)
Inventory	(311,640)	17,743
Deposits for Inventory purchases	(580,800)
Lease Liability	(20,974)	(17,913)
Accounts Payable	(14,376)	11,222
Customer Deposits	305,972
Accrued Liabilities and Other Liabilities	134,708	29,770
Net Cash (used in) operating activities	(410,806)	(125,794)
Investing Activities:
Purchase of Fixed Assets	(23,505)
Purchase of equity method investment		(210,000)	$ (250,000)
Net cash Used in Investing activities	(23,505)	(210,000)
Financing Activities:
Payment of Stock Issuance Costs	(732,355)
Proceeds from exercise of Warrants	1,352	166
Proceeds from exercise of Stock Options	501
Proceeds from Issuance of Common Stock	5,994,424
Net Cash provided by financing activities	5,263,922	166
Net increase (decrease) in Cash	4,829,611	(335,628)
Cash at Beginning of the Year	2,871,694	869,557	869,557
Cash at March 31, 2020 and 2019	7,701,305	533,929	$ 2,871,694
Supplemental Cash Flow Information
Cash Paid for Interest	2,348	1,704
Cash Paid for Income Taxes
Non-Cash Transactions
Common Stock Issued for Conversion of Note and Accrued Interest		211,983
ROU assets and operating lease obligations recognized		847,441
Equity Method Investment recorded to accrued liabilities		$ 40,000

Organization and Basis of Prese

Organization and Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION Trxade Group, Inc. (“ we our Trxade Company Trxade, Inc., operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories and services. Integra Pharma Solutions, LLC, is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products. Community Specialty Pharmacy, LLC, is an accredited independent retail pharmacy with a focus on specialty medications. The company operates with an innovative pharmacy model which offers home delivery services to patients thereby providing convenience. Alliance Pharma Solutions, LLC, has developed a same day Pharma delivery software – Delivmeds.com, and invested in SyncHealth MSO, LLC, a managed services organization during January 2019, which investment was divested in February 2020. Bonum Health, LLC was formed to hold certain telehealth assets acquired in October 2019. The “ Bonum Health Hub On October 9, 2019, the Company’s Board of Directors, and on October 15, 2019, stockholders holding a majority of the Company’s outstanding voting shares, approved resolutions authorizing a reverse stock split of the outstanding shares of the Company’s common stock in the range from one-for-two (1-for-2) to one-for-ten (1-for-10), and provided authority to the Company’s Board of Directors to select the ratio of the reverse stock split in their discretion (the “ Stockholder Authority Reverse Stock Split Proportional adjustments were made to the conversion and exercise prices of the Company’s outstanding warrants and stock options, and to the number of shares issued and issuable under the Company’s stock incentive plans in connection with the Reverse Stock Split. The Reverse Stock Split did not affect any stockholder’s ownership percentage of the Company’s common stock, except to the limited extent that the Reverse Stock Split resulted in any stockholder owning a fractional share. Fractional shares of common stock were rounded up to the nearest whole share based on each holder’s aggregate ownership of the Company. All issued and outstanding shares of common stock, options and warrants to purchase common stock and per share amounts contained in these financial statements, have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented. Basis of Presentation In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2019 as reported in the Company’s Annual Report on Form 10-K have been omitted. Income Per Common Share The following table sets forth the computation of basic and diluted Income per Share: For three months ended March 31, 2020 2019 Numerator: Net Income $ 180,303 $ 125,229 Numerator for basic and diluted EPS - income available to common Shareholders 180,303 $ 125,229 Denominator: Denominator for basic EPS – Weighted average shares 6,971,427 5,560,695 Dilutive Effect of Warrants, Options and Convertible Debt 452,242 437,361 Denominator for diluted EPS – adjusted Weighted average shares and assumed Conversions 7,423,669 5,998,056 Basic income per common share $ 0.03 $ 0.02 Diluted income per common share $ 0.02 $ 0.02

Long Term Debt - Related Partie

Long Term Debt - Related Parties	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Long Term Debt - Related Parties	NOTE 2– LONG TERM DEBT – RELATED PARTIES In October 2018, in connection with the acquisition of Community Specialty Pharmacy, LLC, a $300,000 promissory note was issued to Nikul Panchal, a non-executive officer of the Company, accruing simple interest at the rate of 10% per annum, payable annually, and having a maturity date in October 15, 2021. In October 2019, $75,000 of the note was converted into 25,000 common shares at $3.00 per share. There was a loss recognized on this conversion of $76,500. The outstanding balance at March 31, 2020 is $225,000.

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Shareholders' Equity	NOTE 3 – SHAREHOLDERS’ EQUITY In February 2019, convertible promissory notes issued in 2015 in the amount of $181,500, were amended to include a conversion price of $3.00 per share, and the principal and accrued interest totaling $211,983 was then converted into 70,666 common shares. In February 2019, warrants to purchase 2,778 shares of common stock granted in 2014 with an exercise price of $0.06 per share were exercised for $166 in cash and the Company issued 2,778 common shares. On February 13, 2020, we entered into an underwriting agreement (the “ Underwriting Agreement Representative Offering Closing Date The Company received proceeds of approximately $5.99 million from the Offering. The Company paid the underwriters a cash fee equal to 8% of the aggregate gross proceeds received by the Company in connection with the Offering and reimbursed certain expenses. The total costs of the Offering were $820,586,including $88,213 paid in prior year, which was in deferred offering cost as of December 31, 2019. The net proceeds of the Offering were approximately $5.17 million. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes and possibly to fund acquisitions of other companies, products or technologies. In September 2019, the Company entered into a financial consulting agreement. As compensation, the Company agreed to pay the consultant $15,000 over six months and to grant the consultant warrants to purchase 5,000 shares of common stock with an exercise price of $0.06 per share. The warrants have not been formally granted as of the date of this Report. In February 2020, 22,529 warrants to purchase 22,529 shares of common stock were exercised at $0.06 per share by a related party. In March 2020, 167 options to purchase 167 shares of common stock were exercised at $3.00 per share or $501 in proceeds.

Warrants

Warrants	3 Months Ended
	Mar. 31, 2020
Warrants and Rights Note Disclosure [Abstract]
Warrants	NOTE 4 - WARRANTS For the three month period ended March 31, 2020, warrants to purchase 22,529 shares of common stock were exercised for proceeds of $1,352, and none were granted or forfeited. See “Note 3 – Shareholders’ Equity”. The compensation cost related to the warrants granted in prior year was $79,089 and $0 for the three months ended March 31, 2020 and 2019. The Company’s outstanding and exercisable warrants as of March 31, 2020 are presented below: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Warrants Outstanding as of December 31, 2019 524,480 $ 0.42 2.39 $ 3,273,897 Warrants granted - $ - - - Warrants forfeited - - - - Warrants exercised (22,529 ) $ 0.06 - - Warrants Outstanding as of March 31, 2020 501,951 $ 0.44 2.36 $ 2,693,397

Options

Options	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Options	NOTE 5 – OPTIONS The Company maintains stock option plans under which certain employees are awarded option grants based on a combination of performance and tenure. The stock option plans provide for the grant of up to 1,333,333 shares. For the three month period ended March 31, 2020, 16,667 options were issued, none were forfeited or expired and options to purchase 167 shares of common stock were exercised. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock-based awards on the date of the grant. The following table summarizes the assumptions used to estimate the fair value of the stock options granted during the quarter ended March 31, 2020. 2020 Expected dividend yield 0% Weighted-average expected volatility 133-226% Weighted-average risk-free interest rate 0.25% Expected life of options 10 years Total compensation cost related to stock options granted in the current quarter and prior years was $61,997 and $35,979 for the three months ended March 31, 2020 and 2019, respectively. The following table represents stock option activity for the three month period ended March 31, 2020: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Options Outstanding as of December 31, 2019 346,998 $ 4.39 6.77 $ 817,220 Options Exercisable as of December 31, 2019 207,485 $ 5.29 5.53 $ 312,338 Options granted 16,667 $ 7.50 9.64 - Options forfeited - $ - - - Options expired - $ - - - Options exercised 167 $ 3.00 8.01 - Options Outstanding as of March 31, 2020 363,498 $ 4.53 6.67 $ 557,589 Options Exercisable as of March 31, 2020 216,536 $ 5.32 5.36 $ 184,039

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies	NOTE 6 – CONTINGENCIES In January 2020, we became aware of a complaint filed by Jitendra Jain, Manish Arora, Scariy Kumaramangalam, Harsh Datta and Balvant Arora (collectively, plaintiffs), against our wholly-owned subsidiary, Trxade, Inc. and our Chief Executive Officer, Suren Ajjarapu and Annapurna Gundlapalli, Gajan Mahendiran and Nexgen Memantine, certain unrelated persons (collectively, defendants), in the Circuit Court of Madison County, Alabama (Case:47-CV-2019-902216.00). The complaint alleges causes of actions against the defendants including fraud in the inducement, relating to certain investments alleged to have been made by plaintiffs in Nexgen Memantine, breach of fiduciary duty, conversion and voidable transactions. The complaint relates to certain investments alleged made by the plaintiffs in Nexgen Memantine and certain alleged fraudulent transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company. The complaint seeks $425,000 in compensatory damages and $1,275,000 in punitive damages. The Company and Mr. Ajjarapu deny in their entirety the plaintiffs’ allegations and plan to promptly seek to file a motion to dismiss the plaintiffs’ claims against the Company and Mr. Ajjarapu. The Company and Mr. Ajjarapu further refute any connections for the purpose of the suit to the other named defendants. To the Company’s and Mr. Ajjarapu’s knowledge, the complaint has no merit whatsoever and each of the Company and Mr. Ajjarapu intend to vigorously defend themselves and oppose the relief sought in the complaint. The Company is unable to determine the estimate of the probable or reasonable possible loss or range of losses arising from the above legal proceeding. The Company has filed a motion to dismiss this lawsuit and a hearing was scheduled for March 2020, however, because of the COVID-19 outbreak, the hearing was postponed until further notice from the court.

Leases

Leases	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Leases	NOTE 7 – LEASES The Company elected the practical expedient under ASU 2018-11 “ Leases: Targeted Improvements Lease 1 Lease 2 Initial Lease Term December 2017 to January 2021 November 2018 to November 2023 Renewal Term January 2021 to December 2024 November 2023 to November 2028 Initial Recognition of Right to use assets at January 1, 2019 $ 534,140 $ 313,301 Incremental Borrowing Rate 10 % 10 % The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the operating lease liabilities recorded in the Consolidated Balance Sheet as of March 31, 2020. Amounts due within twelve months of March 31 2020 $ 161,906 2021 166,745 2022 171,756 2023 176,922 2024 149,067 Thereafter 201,097 Total minimum lease payments 1,027,493 Less: effect of discounting (275,656 ) Present value of future minimum lease payments 751,837 Less: current obligations under leases 90,759 Long-term lease obligations $ 661,078 For the three months ended March 31, 2020 and 2019, amortization of assets was $23,635 and $21,744, respectively. For the three months ended March 31, 2020 and 2019, operating lease liabilities paid was $20,974 and $17,913, respectively.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Segment Reporting	NOTE 8 – SEGMENT REPORTING The Company classifies its business interests into reportable segments which are Trxade, Inc., Community Specialty Pharmacy, LLC, Integra Pharma, LLC and Other. Operating segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment. Three Months Ended March 31, 2020 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Other Total Revenue $ 1,519,907 $ 432,929 $ 245,016 $ 5,468 $ 2,203,320 Gross Profit $ 1,519,907 $ 36,108 $ 78,653 $ 5,468 $ 1,640,136 Segment Assets $ 2,055,429 $ 280,514 $ 1,817,170 $ 7,320,791 $ 11,473,904 Segment Profit (Loss) $ 972,993 $ (41,245 ) $ (28,883 ) $ (722,562 ) $ 180,303 Three Months Ended March 31, 2019 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Other Total Revenue $ 1,043,810 $ 442,423 $ 26,288 $ - $ 1,512,521 Gross Profit $ 1,043,810 $ 95,559 $ 7,313 $ - $ 1,146,682 Segment Assets $ 1,474,690 $ 186,496 $ 379,476 $ 1,258,819 $ 3,299,481 Segment Profit (Loss) $ 542,151 $ (6,797 ) $ (71,734 ) $ (338,391 ) $ 125,229

Equity Method Investment

Equity Method Investment	3 Months Ended
	Mar. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investment	NOTE 9 – EQUITY METHOD INVESTMENT In January 2019, the Company, through its wholly-owned subsidiary Alliance Pharma Solution, LLC (“ Alliance SyncHealth PanOptic

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 10 – SUBSEQUENT EVENTS Return of Inventory Deposits In April 2020, $295,800 of inventory deposits were returned to the Company as the providers were out of stock of the specific product ordered. U. S Small Business Association’s Economic Injury Disaster Loan In April 2020, the Company received $10,000 as part of the U.S. Small Business Association’s Economic Injury Disaster Loan program, which provides vital economic support to small businesses to help overcome the temporary loss of revenue they are experiencing as a result of the COVID-19 pandemic. The Company is in the process of returning the money to the Small Business Administration as of the date of this report. Options Granted In April 2020, the Company granted options to purchase 30,353 shares of common stock at an exercise price of $0.06 per share, vesting in August 2020, to a consultant who agreed to provide consulting services for a period of 12 months. 2019 Chief Executive Officer and President Bonuses On April 14, 2020, the Board of Directors (the “ Board Plan 2020 Equity Compensation Awards Also on April 14, 2020, the Compensation Committee approved the grant of options to purchase an aggregate of 31,750 shares of our common stock to certain employees of the Company, in consideration for services to be rendered by such individuals through 2024. The options vest at the rate of 1/4th of such options per year, on the first, second, third and fourth anniversaries of the grant date, subject to such option holders continuing to provide services to the Company on such dates, subject to the terms of the Plan and the option agreements entered into to evidence such grants. The options were granted pursuant to, and are subject to the Plan, and have a term of five years from the grant date. The options have an exercise price of $6.12 per share, the closing price of the Company’s common stock on the date of the grant of such options. On the same date, the Board of Directors approved the grant of (a) 5,000 shares of restricted common stock to the Company’s legal counsel; and (b) 12,500 shares of restricted common stock to Howard A. Doss, the Company’s Chief Financial Officer, which shares are subject to forfeiture and vest at the rate of 1/4th of such shares on July 1 and October 1, 2020 and January 1 and April 1, 2021, subject to such persons continuing to provide services to the Company on such dates, subject to the terms of the Plan and the Restricted Stock Grant Agreements entered into to evidence such awards. Independent Director Compensation Plan On April 14, 2020, the Board of Directors approved an independent director compensation policy (the “ Policy Additionally, each independent member of the Board of Directors is to receive an annual grant of restricted common stock of the Company equal to $55,000 in value, on April 1st of each year, and valued on such same date, based on the closing sales price on such date (or the first business day thereafter), which restricted stock awards will vest at the rate of 1/4th of such awards over the following four calendar quarters, subject to such directors continued service to the Company. In connection with and pursuant to the compensation plan, the three independent members of the Board of Directors (Mr. Donald G. Fell, Dr. Pamela Tenaerts, and Mr. Michael L. Peterson), were awarded 8,987 shares of restricted stock, which vest at the rate of 1/4th of such shares on July 1 and October 1, 2020 and January 1 and April 1, 2021, subject to such persons continuing to provide services to the Company on such dates, subject to the terms of the Plan and the Restricted Stock Grant Agreements entered into to evidence such awards. Employment Agreement with Suren Ajjarapu, Chief Executive Officer Effective on April 14, 2020, we entered into a new employment agreement with Mr. Suren Ajjarapu, our Chief Executive Officer, which replaced and superseded his prior employment agreement with the Company. The agreement, which provides for Mr. Ajjarapu to serve as our Chief Executive Officer, has a term extending through December 31, 2025, provided that the agreement automatically extends for additional one year terms thereafter in the event neither party provides the other at least 60 days prior notice of their intention not to renew the terms of the agreement. The agreement also requires the Board, subject to certain exceptions, to nominate Mr. Ajjarapu to serve on the Board at each stockholders’ meeting which occurs during the term of the agreement and to serve as the Chairman of the Board. Pursuant to the terms of the agreement, Mr. Ajjarapu’s annual compensation package includes (1) a base salary of $300,000 per year, subject to annual increases as determined in the sole discretion of the Compensation Committee (the “ Base Salar Performance Metrics 2020 Restricted Stock

Organization and Basis of Pre_2

Organization and Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Basic and Dilutive Income Per Share	The following table sets forth the computation of basic and diluted Income per Share: For three months ended March 31, 2020 2019 Numerator: Net Income $ 180,303 $ 125,229 Numerator for basic and diluted EPS - income available to common Shareholders 180,303 $ 125,229 Denominator: Denominator for basic EPS – Weighted average shares 6,971,427 5,560,695 Dilutive Effect of Warrants, Options and Convertible Debt 452,242 437,361 Denominator for diluted EPS – adjusted Weighted average shares and assumed Conversions 7,423,669 5,998,056 Basic income per common share $ 0.03 $ 0.02 Diluted income per common share $ 0.02 $ 0.02

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2020
Warrants and Rights Note Disclosure [Abstract]
Schedule of Outstanding and Exercisable Warrants	The Company’s outstanding and exercisable warrants as of March 31, 2020 are presented below: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Warrants Outstanding as of December 31, 2019 524,480 $ 0.42 2.39 $ 3,273,897 Warrants granted - $ - - - Warrants forfeited - - - - Warrants exercised (22,529 ) $ 0.06 - - Warrants Outstanding as of March 31, 2020 501,951 $ 0.44 2.36 $ 2,693,397

Options (Tables)

Options (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Estimate Fair Value of Stock Options	The Company uses the Black-Scholes option pricing model to estimate the fair value of stock-based awards on the date of the grant. The following table summarizes the assumptions used to estimate the fair value of the stock options granted during the quarter ended March 31, 2020. 2020 Expected dividend yield 0% Weighted-average expected volatility 133-226% Weighted-average risk-free interest rate 0.25% Expected life of options 10 years
Schedule of Stock Option Activity	The following table represents stock option activity for the three month period ended March 31, 2020: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Options Outstanding as of December 31, 2019 346,998 $ 4.39 6.77 $ 817,220 Options Exercisable as of December 31, 2019 207,485 $ 5.29 5.53 $ 312,338 Options granted 16,667 $ 7.50 9.64 - Options forfeited - $ - - - Options expired - $ - - - Options exercised 167 $ 3.00 8.01 - Options Outstanding as of March 31, 2020 363,498 $ 4.53 6.67 $ 557,589 Options Exercisable as of March 31, 2020 216,536 $ 5.32 5.36 $ 184,039

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Schedule of Operating Leases	The following table outlines the details: Lease 1 Lease 2 Initial Lease Term December 2017 to January 2021 November 2018 to November 2023 Renewal Term January 2021 to December 2024 November 2023 to November 2028 Initial Recognition of Right to use assets at January 1, 2019 $ 534,140 $ 313,301 Incremental Borrowing Rate 10 % 10 %
Schedule of Future Minimum Payments for Operating Lease Liabilities	The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the operating lease liabilities recorded in the Consolidated Balance Sheet as of March 31, 2020. Amounts due within twelve months of March 31 2020 $ 161,906 2021 166,745 2022 171,756 2023 176,922 2024 149,067 Thereafter 201,097 Total minimum lease payments 1,027,493 Less: effect of discounting (275,656 ) Present value of future minimum lease payments 751,837 Less: current obligations under leases 90,759 Long-term lease obligations $ 661,078

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Schedule of Business Interests Into Reportable Segments	The Company’s chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment. Three Months Ended March 31, 2020 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Other Total Revenue $ 1,519,907 $ 432,929 $ 245,016 $ 5,468 $ 2,203,320 Gross Profit $ 1,519,907 $ 36,108 $ 78,653 $ 5,468 $ 1,640,136 Segment Assets $ 2,055,429 $ 280,514 $ 1,817,170 $ 7,320,791 $ 11,473,904 Segment Profit (Loss) $ 972,993 $ (41,245 ) $ (28,883 ) $ (722,562 ) $ 180,303 Three Months Ended March 31, 2019 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Other Total Revenue $ 1,043,810 $ 442,423 $ 26,288 $ - $ 1,512,521 Gross Profit $ 1,043,810 $ 95,559 $ 7,313 $ - $ 1,146,682 Segment Assets $ 1,474,690 $ 186,496 $ 379,476 $ 1,258,819 $ 3,299,481 Segment Profit (Loss) $ 542,151 $ (6,797 ) $ (71,734 ) $ (338,391 ) $ 125,229

Organization and Basis of Pre_3

Organization and Basis of Presentation (Details Narrative)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Ownership percentage	100.00%
Reverse stock split, description	On October 9, 2019, the Company's Board of Directors, and on October 15, 2019, stockholders holding a majority of the Company's outstanding voting shares, approved resolutions authorizing a reverse stock split of the outstanding shares of the Company's common stock in the range from one-for-two (1-for-2) to one-for-ten (1-for-10), and provided authority to the Company's Board of Directors to select the ratio of the reverse stock split in their discretion (the "Stockholder Authority"). On February 12, 2020, the Board of Directors of the Company approved a stock split ratio of 1-for-6 ("Reverse Stock Split") in connection with the Stockholder Authority and the Company filed a Certificate of Amendment with the Secretary of Delaware to affect the Reverse Stock Split.

Organization and Basis of Pre_4

Organization and Basis of Presentation - Schedule of Basic and Dilutive Income Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income (Loss)	$ 180,303	$ 125,229
Numerator for basic and diluted EPS - income available to common Shareholders	$ 180,303	$ 125,229
Denominator for basic EPS - Weighted average shares	6,971,427	5,560,695
Dilutive Effect of Warrants, Options and Convertible Debt	452,242	437,361
Denominator for diluted EPS - adjusted Weighted average shares and assumed Conversions	7,423,669	5,998,056
Basic income per common share	$ 0.03	$ 0.02
Diluted income per common share	$ 0.02	$ 0.02

Long Term Debt - Related Part_2

Long Term Debt - Related Parties (Details Narrative) - USD ($)	1 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Mar. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Long term debt related party			$ 225,000	$ 225,000
Community Specialty Pharmacy, LLC [Member] | Related Party Promissory Note [Member] | Nikul Panchal [Member]
Debt Instrument [Line Items]
Proceeds from issuance of promissory note		$ 300,000
Interest rate		10.00%
Debt instrument maturity date		Oct. 15, 2021
Debt instrument conversion amount	$ 75,000
Debt instrument conversion shares	25,000
Debt instrument conversion price per share		$ 3
Loss on extinguishment of debt	$ 76,500

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($)	Mar. 31, 2020	Feb. 29, 2020	Feb. 21, 2020	Feb. 18, 2020	Feb. 13, 2020	Sep. 30, 2019	Feb. 28, 2019	Mar. 31, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Warrants to purchase common stock							2,778
Warrant exercise price							$ 0.06
Number of warrants exercised for cash							$ 166
Number of common shares issued for warrants exercised							2,778
Proceeds from offering								$ 5,990,000
Underwriters cash fee percentage								8.00%
Stock offering costs								$ 820,586
Deferred offering costs									$ 88,213
Net issuance cost	$ 5,170,000							$ 5,170,000
Number of options, granted								16,667
Proceeds from common stock								$ 5,994,424
Underwriting Agreement [Member] | Underwriters [Member]
Class of Stock [Line Items]
Sale of common stock				$ 806,452
Financial Consulting Agreement [Member] | Consultant [Member]
Class of Stock [Line Items]
Warrants to purchase common stock	167	22,529				5,000		167
Warrant exercise price	$ 3	$ 0.06				$ 0.06		$ 3
Stock based compensation						$ 15,000
Number of options, granted	167	22,529
Proceeds from common stock	$ 501
Representative [Member] | Underwriting Agreement [Member] | Offering [Member]
Class of Stock [Line Items]
Sale of common stock					$ 806,452
Sale of stock price per share			$ 6.50
Representative [Member] | Underwriting Agreement [Member] | Over-Allotment Option [Member]
Class of Stock [Line Items]
Stock issued during period			115,767
Convertible Promissory Note [Member]
Class of Stock [Line Items]
Convertible promissory notes							$ 181,500
Debt instrument conversion price per share							$ 3
Debt principal and accrued interest, amount							$ 211,983
Debt instrument conversion shares							70,666

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Feb. 28, 2019
Class of Warrant or Right [Line Items]
Warrants to purchase common stock			2,778
Proceeds from exercise of warrants	$ 1,352	$ 166
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase common stock	22,529
Proceeds from exercise of warrants	$ 1,352
Stock based compensation	$ 79,089	$ 0

Warrants - Summary of Assumptio

Warrants - Summary of Assumptions Used to Estimate Fair Value of Warrants Granted (Details)	Mar. 31, 2020
Expected Dividend Yield [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	0
Weighted-average Expected Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	217
Weighted-average Risk-free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	2.75
Expected Life of Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants, term	5 years

Warrants - Schedule of Outstand

Warrants - Schedule of Outstanding and Exercisable Warrants (Details)	3 Months Ended
	Mar. 31, 2020USD ($)$ / sharesshares
Warrants and Rights Note Disclosure [Abstract]
Number of Outstanding Shares, Warrants Outstanding Beginning | shares	524,480
Number of Outstanding Shares, Warrants Granted | shares
Number of Outstanding Shares, Warrants Forfeited | shares
Number of Outstanding Shares, Warrants Exercised | shares	(22,529)
Number of Outstanding Shares, Warrants Outstanding Ending | shares	501,951
Weighted Average Exercise Price, Outstanding Beginning | $ / shares	$ 0.42
Weighted Average Exercise Price, Warrants Granted | $ / shares
Weighted Average Exercise Price, Warrants Forfeited | $ / shares
Weighted Average Exercise Price, Warrants Exercised | $ / shares	0.06
Weighted Average Exercise Price, Outstanding Ending | $ / shares	$ 0.44
Contractual Life Warrants Outstanding, Beginning	2 years 4 months 20 days
Contractual Life Warrants Outstanding, Granted	0 years
Contractual Life Warrants Outstanding, Forfeited	0 years
Contractual Life Warrants Outstanding, Exercised	0 years
Contractual Life Warrants Outstanding Ending	2 years 4 months 9 days
Aggregate Intrinsic Value Outstanding Beginning | $	$ 3,273,897
Aggregate Intrinsic Value Outstanding Ending | $	$ 2,693,397

Options (Details Narrative)

Options (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted	16,667
Number of Options, Forfeited
Number of Options, Expired
Stock option exercised price shares	167
Stock options, compensation cost	$ 61,997	$ 35,979
Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted	1,333,333

Options - Schedule of Estimate

Options - Schedule of Estimate Fair Value of Stock Options (Details)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Expected dividend yield	0.00%
Weighted-average expected volatility, minimum	133.00%
Weighted-average expected volatility, maximum	226.00%
Weighted-average risk-free interest rate	0.25%
Expected life of options	10 years

Options - Schedule of Stock Opt

Options - Schedule of Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2020USD ($)$ / sharesshares
Share-based Payment Arrangement [Abstract]
Number of Options Outstanding, Beginning Balance | shares	346,998
Number of Options Exercisable, Beginning Balance | shares	207,485
Number of Options, Granted | shares	16,667
Number of Options, Forfeited | shares
Number of Options, Expired | shares
Number of Options, Exercised | shares	167
Number of Options Outstanding, Ending Balance | shares	363,498
Number of Options Exercisable, Ending Balance | shares	216,536
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 4.39
Weighted Average Exercise Price Exercisable, Beginning Balance | $ / shares	5.29
Weighted Average Exercise Price, Granted | $ / shares	7.50
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Exercise Price, Expired | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares	3
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	4.53
Weighted Average Exercise Price Exercisable, Ending Balance | $ / shares	$ 5.32
Contractual Life in Years Outstanding, Beginning Balance	6 years 9 months 7 days
Contractual Life in Years Exercisable, Beginning Balance	5 years 6 months 10 days
Contractual Life in Years, Granted	9 years 7 months 21 days
Contractual Life in Years, Forfeited	0 years
Contractual Life in Years, Expired	0 years
Contractual Life in Years, Exercised	8 years 4 days
Contractual Life in Years Outstanding, Ending Balance	6 years 8 months 2 days
Contractual Life in Years Exercisable, Ending Balance	5 years 4 months 9 days
Intrinsic Value Outstanding, Beginning Balance | $	$ 817,220
Intrinsic Value Exercisable, Beginning Balance | $	312,338
Intrinsic Value, Exercised | $
Intrinsic Value Outstanding, Ending Balance | $	557,589
Intrinsic Value Exercisable, Ending Balance | $	$ 184,039

Contingencies (Details Narrativ

Contingencies (Details Narrative)	1 Months Ended
	Jan. 31, 2020USD ($)
Compensatory Damages [Member]
Complaint seeks	$ 425,000
Punitive Damages [Member]
Complaint seeks	$ 1,275,000

Leases (Details Narrative)

Leases (Details Narrative)	3 Months Ended
	Mar. 31, 2020USD ($)Integer	Mar. 31, 2019USD ($)
Leases [Abstract]
Operating leases units | Integer	2
Operating lease amortization of right of use lease assets	$ 23,635	$ 21,744
Operating lease liabilities paid	$ 20,974	$ 17,913

Leases - Schedule of Operating

Leases - Schedule of Operating Leases (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Initial Recognition of Right to use assets at January 1, 2019	$ 734,075	$ 757,710
Lease 1 [Member]
Lessee, Lease, Description [Line Items]
Initial Lease Term	December 2017 to January 2021
Renewal Term	January 2021 to December 2024
Initial Recognition of Right to use assets at January 1, 2019	$ 534,140
Incremental Borrowing Rate	10.00%
Lease 2 [Member]
Lessee, Lease, Description [Line Items]
Initial Lease Term	November 2018 to November 2023
Renewal Term	November 2023 to November 2028
Initial Recognition of Right to use assets at January 1, 2019	$ 313,301
Incremental Borrowing Rate	10.00%

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Payments for Operating Lease Liabilities (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
2020	$ 161,906
2021	166,745
2022	171,756
2023	176,922
2024	149,067
Thereafter	201,097
Total minimum lease payments	1,027,493
Less: effect of discounting	(275,656)
Present value of future minimum lease payments	751,837
Less: current obligations under leases	90,759	$ 87,350
Long-term lease obligations	$ 661,078	$ 685,461

Segment Reporting - Schedule of

Segment Reporting - Schedule of Business Interests Into Reportable Segments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Segment Reporting Information [Line Items]
Revenue	$ 2,203,320	$ 1,512,521
Gross Profit	1,640,136	1,146,682
Segment Assets	11,473,904	3,299,481	$ 5,571,494
Segment Profit/Loss	180,303	125,229
Trxade, Inc. [Member]
Segment Reporting Information [Line Items]
Revenue	1,519,907	1,043,810
Gross Profit	1,519,907	1,043,810
Segment Assets	2,055,429	1,474,690
Segment Profit/Loss	972,993	542,151
Community Specialty Pharmacy, LLC [Member]
Segment Reporting Information [Line Items]
Revenue	432,929	442,423
Gross Profit	36,108	95,559
Segment Assets	280,514	186,496
Segment Profit/Loss	(41,245)	(6,797)
Integra Pharma, LLC [Member]
Segment Reporting Information [Line Items]
Revenue	245,016	26,288
Gross Profit	78,653	7,313
Segment Assets	1,817,170	379,476
Segment Profit/Loss	(28,883)	(71,734)
Other [Member]
Segment Reporting Information [Line Items]
Revenue	5,468
Gross Profit	5,468
Segment Assets	7,320,791	1,258,819
Segment Profit/Loss	$ (722,562)	$ (338,391)

Equity Method Investment (Detai

Equity Method Investment (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		12 Months Ended
	Apr. 30, 2019	Jan. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Jan. 31, 2020	Nov. 01, 2019	Aug. 01, 2019	May 01, 2019
Schedule of Equity Method Investments [Line Items]
Payment to acquire equity interest				$ 210,000	$ 250,000
Equity method investment ownership percentage			100.00%
Investment loss recognized					$ 250,000
Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Stock issued during period			378,888
Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Stock issued during period			2,462,773
SyncHealth MSO, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership percentage							7.00%	6.00%	6.00%
Alliance Pharma Solution, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Payment to acquire equity interest	$ 40,000	$ 250,000		$ 210,000
Equity method investment ownership percentage		30.00%
Alliance Pharma Solution, LLC [Member] | SyncHealth MSO, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership percentage		30.00%			30.00%
PanOptic Health, LLC [Member] | SyncHealth MSO, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership percentage		70.00%				30.00%
SyncHealth MSO, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership percentage						51.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Dec. 31, 2020	Apr. 30, 2020	Apr. 14, 2020	Mar. 31, 2020	Dec. 31, 2020
Subsequent Event [Line Items]
Stock option granted common stock				16,667
Exercise price of options granted				$ 7.50
Subsequent Event [Member]
Subsequent Event [Line Items]
Inventory deposits		$ 295,800
Subsequent Event [Member] | Legal Counsel [Member]
Subsequent Event [Line Items]
Restricted common stock			5,000
Subsequent Event [Member] | 2020 Equity Compensation Awards [Member]
Subsequent Event [Line Items]
Stock option granted common stock			31,750
Exercise price of options granted			$ 6.12
Compensation awards description			Consideration for services to be rendered by such individuals through 2024. The options vest at the rate of 1/4th of such options per year, on the first, second, third and fourth anniversaries of the grant date
Subsequent Event [Member] | U.S. Small Business Association [Member] | Economic Injury Disaster Loan Program [Member]
Subsequent Event [Line Items]
Proceeds from loan		$ 10,000
Subsequent Event [Member] | Consultant [Member]
Subsequent Event [Line Items]
Stock option granted common stock		30,353
Subsequent Event [Member] | Aijarapu [Member] | 2019 Equity Incentive Plan [Member]
Subsequent Event [Line Items]
Bonus description			Company's Chief Executive Officer and Prashant Patel, the Company's President, of bonuses equal to 1% of the Company's outstanding shares, equivalent to 74,484 shares of common stock
Number of shares of common stock			74,484
Subsequent Event [Member] | Mr. Patel [Member] | 2019 Equity Incentive Plan [Member]
Subsequent Event [Line Items]
Number of shares of common stock			50,000
Subsequent Event [Member] | Howard A. Doss [Member]
Subsequent Event [Line Items]
Compensation awards description			Shares are subject to forfeiture and vest at the rate of 1/4th of such shares on July 1 and October 1, 2020 and January 1 and April 1, 2021
Restricted common stock			12,500
Subsequent Event [Member] | Board of Directors [Member]
Subsequent Event [Line Items]
Restricted common stock			55,000
Subsequent Event [Member] | Board of Directors [Member] | Independent Director Compensation Policy [Member]
Subsequent Event [Line Items]
Receive a annual retainer for services			$ 35,000
Subsequent Event [Member] | Chairperson of the Compensation Committee and Nominating and Corporate Governance Committee [Member] | Independent Director Compensation Policy [Member]
Subsequent Event [Line Items]
Receive a annual retainer for services			10,000
Subsequent Event [Member] | Chairperson of the Audit Committee [Member] | Independent Director Compensation Policy [Member]
Subsequent Event [Line Items]
Receive a annual retainer for services			$ 20,000
Subsequent Event [Member] | Mr. Donald G. Fell, Dr. Pamela Tenaerts and Mr. Michael L. Peterson [Member]
Subsequent Event [Line Items]
Restricted common stock			8,987
Subsequent Event [Member] | Ajjarapu [Member] | Employment Agreement [Member]
Subsequent Event [Line Items]
Compensation awards description			Effective on April 14, 2020, we entered into a new employment agreement with Mr. Suren Ajjarapu, our Chief Executive Officer, which replaced and superseded his prior employment agreement with the Company. The agreement, which provides for Mr. Ajjarapu to serve as our Chief Executive Officer, has a term extending through December 31, 2025, provided that the agreement automatically extends for additional one year terms thereafter in the event neither party provides the other at least 60 days prior notice of their intention not to renew the terms of the agreement.
Automobile allowance					$ 1,000
Subsequent Event [Member] | Ajjarapu [Member] | Employment Agreement [Member] | Base Salary [Member]
Subsequent Event [Line Items]
Compensation awards description			Mr. Ajjarapu's annual compensation package includes (1) a base salary of $300,000 per year, subject to annual increases as determined in the sole discretion of the Compensation Committee (the "Base Salary"), and (2) a performance bonus equal to up to 100% of his Base Salary each year, based on the Company meeting certain performance metrics as determined from time to time by the Compensation Committee and Mr. Ajjarapu ("Performance Metrics"). Additionally, in the event that Mr. Ajjarapu meets at least 70% of the requirements for any annual performance bonus, as determined in the reasonable discretion of the Compensation Committee of the Board, Mr. Ajjarapu's Base Salary is increased by 20%.
Annual compensation			$ 300,000
Subsequent Event [Member] | Ajjarapu [Member] | Employment Agreement [Member] | Performance Metrix [Member]
Subsequent Event [Line Items]
Compensation awards description	For 2020, those performance metrics include ((1) hitting a revenue goal of $12.5 million (50% of restricted shares described below vest); (2) reaching 50,000 Bonum Health patients (30% of restricted shares described below vest); (3) placing e-hubs in 100 stores (10% of restricted shares described below vest); and (4) obtaining net operating income of 10% of total sales (20% of restricted shares described below vest). The determination of whether the Performance Metrics have been met are determined in the reasonable discretion of the Compensation Committee, no later than 90 days after (a) December 31, 2020, in connection with the 2020 Performance Metrics; and (b) the end of such calendar year for subsequent years.
Revenue	$ 12,500,000
Subsequent Event [Member] | Ajjarapu [Member] | Employment Agreement [Member] | 2020 Restricted Stock Awards [Member]
Subsequent Event [Line Items]
Restricted common stock					49,020